IRON (Disc Medicine) Ending Cash Position: $98.92 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRON Disc Medicine Inc IRON
34 GF Score
Price $77.00
! 3 Warning Signs
View Full Analysis

What is Disc Medicine Ending Cash Position?

Disc Medicine IRON -2.79% 34 Ending Cash Position is $98.92 Mil as of Jun. 2026. GuruFocus rates IRON with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Disc Medicine's Ending Cash Position for the quarter that ended in Jun. 2026 was $98.92 Mil.

Disc Medicine's quarterly Ending Cash Position declined from Dec. 2025 ($91.39 Mil) to Mar. 2026 ($89.16 Mil) but then increased from Mar. 2026 ($89.16 Mil) to Jun. 2026 ($98.92 Mil).

Disc Medicine's annual Ending Cash Position declined from Dec. 2023 ($360.62 Mil) to Dec. 2024 ($192.67 Mil) and declined from Dec. 2024 ($192.67 Mil) to Dec. 2025 ($91.39 Mil).

Disc Medicine Ending Cash Position Related Terms

Disc Medicine Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Disc Medicine's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disc Medicine Ending Cash Position Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 88.21 194.79 360.62 192.67 91.39

Disc Medicine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.58 140.90 91.39 89.16 98.92
IRON
34GF Score
Disc Medicine Inc IRON
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disc Medicine Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Disc Medicine's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=192.672+-101.285
=91.39

Disc Medicine's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=89.155+9.763
=98.92

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $98.92 Mil mean?
Disc Medicine (IRON) has a Ending Cash Position of $98.92 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Disc Medicine and its competitors.
Is Disc Medicine's Ending Cash Position too high?
Disc Medicine's current Ending Cash Position is $98.92 Mil. Overall, Disc Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's Ending Cash Position compare to CLDX and MBX?
Disc Medicine's Ending Cash Position of $98.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Disc Medicine and its competitors. Disc Medicine's current Ending Cash Position is $98.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current Ending Cash Position of $98.92 Mil. The current Ending Cash Position is $98.92 Mil. Disc Medicine's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Disc Medicine (IRON), the current Ending Cash Position is $98.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disc Medicine Business Description

Address 321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
34GF Score

Get the complete analysis for IRON

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.00
Price